Maxona Pharmaceuticals

MAXONA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company leveraging innovation to develop the next generation of therapies to help patients maximize life. MAXONA's initial focus is on addressing the urgent need for new effective therapies that treat acute and chronic pain, without the side effects and addiction risks associated with NSAIDS and opioids. MAXONA's lead compound, MAX-001 is a non-opioid, non-NSAID oral therapy with a novel mechanism of action that is initially being developed in the U.S. to treat acute and chronic pain. MAX-001 is a patent protected optimized formulation of nefopam. which is widely used and extensively studied outside the U.S. to treat acute and chronic pain. MAXONA has assembled a highly experienced and well recognized leadership team with a proven record of successfully developing and commercializing effective therapeutics. With deep experience in all areas of clinical development and commercialization, the leadership team is well-equipped to realize MAXONA's vision to help patients maximize life.